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Abstract
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. Its
incidence has grown alongside the increasing global prevalence of type 2 diabetes, obesity, and metabolic syndrome. The risk of progression to hepatocellular carcinoma for nonalcoholic steatohepatitis patients over 5 years
is 8%, and despite targeted and immunotherapy treatment advances, HCC maintains a bleak 5-year survival
of 19%. NAFLD’s primary risk factors are components of metabolic syndrome as well as possible sleep disturbances. NAFLD is most common among men 50-60 years of age, though incidence in women catches up after
menopause. In the US, Hispanics are most likely to develop NAFLD and African Americans least likely, in part
due to the prevalence of the PNPLA3 gene variant. With NAFLD risk factors especially prevalent in underserved
populations and developing nations, public health interventions, earlier diagnosis, and novel treatments could
curb the growing disease burden.
Key words: risk factor, incidence, prevalence, etiology, mortality.
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Introduction

Diagnostic criteria

Non-alcoholic fatty liver disease (NAFLD) has
grown in incidence to become the most common
chronic liver disease worldwide [1] and is projected to
surpass alcoholic liver disease as the leading cause of
liver transplantation in the United States by 2030 [2].
NAFLD can be classified based on histological progression: non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NASH cirrhosis, and
NASH-related hepatocellular carcinoma (HCC) [2].
A better understanding of NAFLD epidemiology and
risk factors may facilitate ongoing prevention efforts
aimed at reducing the quality of life burden, demand
for a liver transplant, and risk of HCC all posed by the
global rise in NAFLD.

NAFLD is a diagnosis of exclusion – it is defined as
hepatic fat accumulation of greater than 5% of total liver
volume without a known secondary cause [3]. While it
may histologically and clinically resemble alcohol-induced liver disease, patients with NAFLD do not have
a significant history of alcohol consumption (typically
considered > 30 g daily for over 10 years for men and
20 g daily for women). Physicians must also exclude
infectious hepatitis (hepatitis B, C, and D patients can
develop chronic infection, leading to cirrhosis) as well
as hepatitis induced by medications (acetaminophen,
aspirin, corticosteroids, amiodarone, isoniazid, cytotoxic chemotherapies, and more), endogenous toxic compounds (hemochromatosis, Wilson’s disease), autoim-
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mune disorders (autoimmune hepatitis, systemic lupus
erythematosus, sarcoidosis) and ischemia (thromboses,
Budd-Chiari syndrome) [3].
While the gold standard remains liver biopsy, new
non-invasive modalities are being used to facilitate the
diagnosis of NAFLD. Hepatic ultrasonography, magnetic resonance imaging (MRI), and computed tomography (CT) are all utilized in detecting fatty infiltration in
the liver. Levels of aminotransferase enzymes (alanine
aminotransferase [ALT] and aspartate aminotransferase [AST]) have also been used with varying degrees of
success as a screening tool for liver disease. Ultrasonography has become the standard modality for screening
for moderate to severe fatty liver disease. Nevertheless,
a biopsy is essential to differentiate steatosis (fatty liver)
from NASH, which has a higher risk of disease progression. Early diagnosis of NASH can have implications for
management, allowing patients to try newly approved
medications and off-label developmental therapies
in the hopes of preventing progression to cirrhosis or
HCC. A biopsy is indicated for all NAFLD patients
(confirmed with chronically elevated aminotransferase
levels and imaging) who are 65 years and older, have
symptoms of metabolic syndrome, or as a means to rule
out other causes of liver diseases after appropriate imaging/bloodwork has been exhausted.

Histological progression
The steatosis seen in NAFLD is “macro-steatosis”, as
opposed to micro-steatosis characteristic of Reye syndrome, which is fulminant hepatitis following aspirin administration in children with viral illness [4]. A diagnosis
of NASH requires four components: steatosis, inflammation (steatohepatitis), fibrosis, and cellular ballooning
[5]. Variability among pathologists in the identification
of cellular ballooning (an indicator of hepatocyte apoptosis) may result in fewer patients meeting the criteria for
NASH and receiving appropriate management or enrollment in clinical trials [6]. NASH may also present with
Mallory-Denk bodies (eosinophilic inclusions indicative
of apoptosis) or councilman bodies (remnants of hepatocytes undergoing apoptosis) [7, 8].
Non-invasive methods for the diagnosis of NASH
are currently under development, including the biomarker cytokeratin 18 [9], as well as the predictive
NAFLD fibrosis score and FIB-4, which are derived
from clinical presentation (i.e. age, body mass index
[BMI], hyperglycemia, platelet count, albumin and
AST/ALT ratio) [10].
NASH can progress to “cryptogenic cirrhosis”,
which is defined as cirrhosis of an unclear origin. While
progressing, NASH loses its prototypical inflammation

290

and steatosis, leaving behind only the bridging fibrosis characteristic of cirrhosis [11]. Cirrhosis can result
in jaundice, asterixis, portal hypertension (leading to
portocaval anastomoses such as esophageal varices,
which are the most common acute cause of death), encephalopathy, and thrombocytopenia [11]. End-stage
cirrhosis requires liver transplantation for survival and
also increases the risk of HCC development by 45-fold
(discussed further under “risk of progression”) [12].

Epidemiology
Incidence
Incidence rates reported are highly variable due
to variable disease presentation, different screening
standards across nations, and sensitivity discrepancies
between diagnostic modalities. A retrospective study
from England estimated the incidence at 29/100,000
[13], while a Japanese study based on aminotransferase levels found an incidence of 31/1,000 person-years
[14], over a thousand-fold greater. A pooled metaanalysis among Asian nations estimated the incidence at 52/1,000 person-years [15]. These disparate
estimates of NAFLD warrant further meta-analysis,
with many studies suggesting that incidence rates are
grossly underestimated due to limited diagnosis of
early-stage disease [15].

Prevalence
The global prevalence of NAFLD is estimated at
25.2% (over 2 billion people worldwide), though studies
suggest that statistics may be underreported due to lack
of access to healthcare and variable clinical presentation
[15, 16]. Estimates for prevalence can also vary based
on diagnostic methods. In the US, from 1988 to 1992,
7.9% of the general population tested with elevated aminotransferases, and 69% of these had unexplained liver
disease (i.e. NAFLD) [17]. Meanwhile, the prevalence
of signs of fatty liver infiltration on ultrasound ranged
from 22% in the Netherlands [18] to 33% in Bangladesh
[19] and 46% in the United States [20]. Magnetic resonance spectroscopy (MRS) is likewise highly sensitive
for fatty infiltrates, with one study from the US reporting a prevalence of 33.6% [21].
The prevalence of NAFLD is rising in developing
nations, likely due to the adoption of the “Western” diet
and lifestyle and consequent rise in metabolic syndrome.
Meta-regression of global epidemiological studies estimates that NAFLD prevalence has increased globally
from 15% in 2005 to 25% in 2015, and is projected to
continue growing [15]. The highest prevalence has been
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recorded in the Middle East and South America, while
South and East Africa have the lowest [15].
One-quarter of patients with NAFLD in the US are
estimated to progress to NASH [22]. The prevalence of
NASH, which carries a greater risk of progression (cirrhosis and HCC) and mortality, is estimated at 1.5-6.5%
worldwide [15, 16]. The prevalence of NASH in the US
is predicted to increase by 55% by the year 2030, thus
becoming the leading cause of liver transplant [2].

Risk of progression to cirrhosis, HCC,
and mortality
Out of the NAFLD spectrum, only NASH has been
shown to progress to cirrhosis and HCC [23]. Of the
estimated 25% of NAFLD patients who progress to
NASH, 21-26% are at risk of progression to cirrhosis
over 8 years [24]. Cirrhosis further increases the risk
of progression to HCC and/or hepatic failure leading
to the need for a transplant, with the stage of fibrosis
being a reliable prognosticator of progression, though
cirrhosis in not necessary for HCC.
The incidence of HCC has increased in parallel
with NAFLD globally. Since 1973, HCC incidence has
grown 4-fold worldwide [25]. In the US, the incidence
of HCC has more than tripled from 2.6/100,000 in 1975
to 8.9/100,000 in 2017 [26]. Advanced fibrosis, as seen
in NASH, carries an 8% 5-year cumulative incidence
rate for HCC, almost one thousand times greater than
the risk for the general population [27]. While the risk
of NAFLD-related HCC is low, the risk of NASH-related HCC is 5.29 cases per 1,000 person-years [15].
This reflects a 9% annual increase in HCC caused by
NAFLD and NASH from 2004 to 2009 [15]. NAFLD
accounts for approximately 8% of HCC diagnoses [28].
While cirrhosis is a significant risk factor for the
development of HCC, studies suggest that 35-50% of
NAFLD patients who progress to HCC never develop
cirrhosis [29]. Among patients with NAFLD, liver-related mortality was the third-leading cause of death following cardiovascular disease and malignancy. In contrast,
among the general population, liver-related mortality
is the 12th leading cause of death [30]. Mortality from
NAFLD is increasing in the United States. The average
life expectancy among NAFLD patients is estimated at
64.4 years, more than 10 years less than the general population life expectancy of 78.6 years [31].
HCC is among the most fatal malignancies, with
a 5-year survival rate of 19.6% in the US. Patients presenting with localized disease have a survival of 34.2%,
while patients diagnosed with distant metastases
(most commonly the lungs) have a 5-year survival of
only 2.5%. HCC accounted for approximately 30,000
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deaths in 2020 (5% of all cancer deaths), of which an
estimated 2,500 were likely caused by NAFLD [26].
Advances in early detection and treatment modalities have increased survival from 1.9% in 1975 [26].
First-line treatment options as recommended by the
NCCN guidelines include small molecule vascular
endothelial growth factor (VEGF) inhibitors such as
sorafenib, which interfere with tumor angiogenesis,
and since approval in 2017, PD-1 inhibitors (checkpoint inhibitors) such as nivolumab and pembrolizumab, which inhibit tumor immunosuppression and
activate CD8 T-cells targeting the tumor [32].
Active surveillance of those with risk factors such
as NAFLD, a history of alcoholism or chronic hepatitis
infection (HBV, HCV, HDV) can facilitate earlier detection of HCC and improved survival rates. Primary
prevention by reducing rates of obesity, diabetes, and
other metabolic syndromes could curb the disease
burden of HCC, with NAFLD projected to become the
leading contributor [33].

Non-modifiable risk factors
Genetic predisposition
The variability in NAFLD development among
those with predisposing lifestyle risk factors suggests
a genetic, heritable component. Genetic variants in or
near several identified loci (TM6SF2, NCAN, PNPLA3,
and PPP1R3B) have been shown to account for 27% of
disease heritability within families [34]. Many of these
variants have been found to increase disease risk independently of the primary contributing lifestyle factors,
such as obesity and diabetes [35, 36].

Gender and age
Men are at greater risk of NAFLD and NASH, at least
until after menopause when women lose the apparent
protective effect of estrogen and their risk becomes comparable to that of men. The peak incidence of NAFLD is
noted in the 50-60 age range in men and the 60-70 age
range in women due to later disease development following the loss of the protective effects of estrogen.

Race/ethnicity
Among US ethnic groups, Hispanics have been
found to incur the greatest risk of NAFLD, while African Americans have the lowest risk. Some studies find
that Hispanics have almost double the prevalence as
compared to African Americans (45-58% vs. 24-35%),
with those of Mexican origin have the highest preva-
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lence among Hispanics [20, 31, 37]. Specifically, variants of the predisposing PNPLA3 gene variants have
been observed in the highest proportions among
Hispanics and the lowest proportions among African
Americans, likely explaining some of the ethnic variation [38]. Socioeconomic status and the strength of
association of NAFLD lifestyle risk factors vary among
ethnicities, painting a complex and yet-to-be-elucidated picture of drivers for disease pathogenesis [39].

Modifiable risk factors
Type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is among the
most significant independent risk factors for NAFLD.
The insulin insensitivity seen in T2DM causes a discrepancy between energy production and consumption, stimulating lipolysis in peripheral adipocytes and
deposition of these excess triglycerides in the liver, resulting in steatosis. NAFLD is considered the hepatic
component of “metabolic syndrome”, and may in turn
increase the risk of T2DM and cardiovascular metabolic complications [40].
55.5% of global T2DM patients have been diagnosed with NAFLD by MRS and 59.7% by ultrasound
or aminotransferases. In the US, the rate of NAFLD
among T2DM patients is estimated as 51.8% by MRS
and 53.1% by other diagnostic methods, which is slightly lower, likely due to better disease management [41].
37.3% of T2DM patients in the US progress to NASH
when diagnosed by liver biopsy, with advanced fibrosis
being observed in 17.0% of T2DM patients [41]. According to a recent estimate, 18.2 million people in the
US have T2DM and NAFLD, with 6.4 million having
NASH [42]. The global prevalence of T2DM rose from
4.7% in 1980 to 8.5% in 2014 [43], which may help explain the global rise in NAFLD over the same period.
T2DM increases the risk of unpreventable, significant disease burden from liver disease, and poorer
long-term outcomes. T2DM predisposes to higher
rates of fibrotic progression [44], cirrhosis [40], hepatocellular carcinoma [45], and mortality both due to
liver-related and cardiovascular causes [46]. Over the
next 20 years, NAFLD in T2DM is estimated to account for $55.8 billion in expenditures, 65,000 transplants, 1.37 million cardiovascular-related deaths, and
812,000 liver-related deaths [42].

Obesity and metabolic syndrome
Obesity is a related modifiable risk factor for
NAFLD. Although obesity is highly associated with
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T2DM (both are components of the so-called “metabolic syndrome”), multivariate analysis has shown
an independent association with NAFLD and NASH
[47]. Obesity predisposes to insulin insensitivity, energy imbalance, and lipolysis, with a similarly suggested
NAFLD pathogenesis as T2DM. NAFLD is also associated with hyperlipidemia (69% of NAFLD patients),
hypertension (39%), and metabolic syndrome (42%),
which is defined as all of the preceding conditions concurrently [15].
The global prevalence of NAFLD among the obese
is estimated in the range 30-37% [15]. Meanwhile,
among global NAFLD patients, 51% are reported to be
obese [15]. Abdominal obesity in particular (so-called
“an apple”, as opposed to “pear”, distribution) is most
strongly associated with NAFLD [8], with increasing
visceral adiposity increasing the risk of NAFLD in
a dose-dependent manner [48]. Multiple studies have
shown a correlation between weight gain and NAFLD
incidence, with even a 2 kg gain within a normal BMI
range resulting in a significantly increased risk of hepatic steatosis on ultrasound [49]. Obesity has also
been shown to act as an additive risk factor for liver
disease with alcohol consumption, increasing the risk
of steatosis among drinkers by over 2-fold [2, 22].

Diet
While increased caloric intake is a risk factor for
both obesity and T2DM, certain food groups may
predispose to NAFLD in particular. Sucrose (sugar) is
composed of both fructose and glucose. Unlike glucose
and galactose, fructose has an unregulated entry from
the gut lumen via the GLUT-5 channel and complete
hepatic extraction, thus increasing the risk of “energy
overload”, diabetes, and NAFLD [50]. Consumption
of beverages with sucrose or high-fructose corn syrup
has increased five-fold in the US since 1950. One study
found that drinking two such drinks daily for only six
months induced features of NAFLD (markers of liver
fat) and led to increased body weight and markers of
cardiovascular disease [51]. In a separate study, NAFLD
patients were also more likely to eat fast food often
(p = 0.049) and not exercise regularly (p = 0.02) [20].

Sleep deprivation
Sleep deprivation and poor sleep quality are known
to increase the risk of obesity by disrupting metabolic
and hunger signaling, such as levels of glucocorticoids,
leptin, peptide Y, and ghrelin. However, on top of the
increased risk of obesity, population cohort studies suggest that sleep deprivation may be independently associ-
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ated with NAFLD with an odds ratio of 1.28 in men and
1.71 in women. Poor sleep quality likewise increased the
risk to a lesser degree [52]. Counterintuitively, a more
recent study found that sleep duration of over 8 hours
increased the risk of NAFLD development [53]. The
relationship between sleep and NAFLD is complex and
has been posited to be mediated by inflammatory cytokines such as interleukin 6 (IL-6) and tumor necrosis
factor α (TNF-α) [54], leading to disturbances in the
hypothalamic-pituitary-adrenal axis [55] as well as insulin/glucagon metabolic regulation [56].

Conclusions
NAFLD has become the most common chronic
liver disease around the world and is only projected
to grow in the coming decades alongside obesity and
metabolic syndrome. NAFLD is projected to become
the leading cause of liver transplant in the US by the
year 2030. NAFLD refers to a family of progressive liver pathologies of unknown (non-alcoholic, infectious,
or toxin-mediated) etiology, which can ultimately
progress to cirrhosis and hepatocellular carcinoma,
as well as increasing the risk of mortality from cardiovascular disease. The greatest risk factors for NAFLD
include components of metabolic syndrome such as
obesity and T2DM. The public health burden is compounded by the fact that these risk factors are particularly prevalent in underserved populations, decreasing
the chance of early diagnosis, which could delay the
progression of the disease. A stronger understanding
of NAFLD pathogenesis and risk factors could inform
public health measures and novel treatment approaches aimed towards curbing the growing disease burden
from irreversible and fatal sequelae such as cirrhosis
and hepatocellular carcinoma.
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